Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli, Hervé Avet-Loiseau, David C Wedge, Peter Van Loo, Ludmil B Alexandrov, Inigo Martincorena, Kevin J Dawson, Francesco Iorio, Serena Nik-Zainal, Graham R Bignell, Jonathan W Hinton, Yilong Li, Jose M C Tubio, Stuart McLaren, Sarah O' Meara, Adam P Butler, Jon W Teague, Laura Mudie, Elizabeth Anderson, Naim Rashid, Yu-Tzu Tai, Masood A Shammas, Adam S Sperling, Mariateresa Fulciniti, Paul G Richardson, Giovanni Parmigiani, Florence Magrangeas, Stephane Minvielle, Philippe Moreau, Michel Attal, Thierry Facon, P Andrew Futreal, Kenneth C Anderson, Peter J Campbell, Nikhil C Munshi, Niccolo Bolli, Hervé Avet-Loiseau, David C Wedge, Peter Van Loo, Ludmil B Alexandrov, Inigo Martincorena, Kevin J Dawson, Francesco Iorio, Serena Nik-Zainal, Graham R Bignell, Jonathan W Hinton, Yilong Li, Jose M C Tubio, Stuart McLaren, Sarah O' Meara, Adam P Butler, Jon W Teague, Laura Mudie, Elizabeth Anderson, Naim Rashid, Yu-Tzu Tai, Masood A Shammas, Adam S Sperling, Mariateresa Fulciniti, Paul G Richardson, Giovanni Parmigiani, Florence Magrangeas, Stephane Minvielle, Philippe Moreau, Michel Attal, Thierry Facon, P Andrew Futreal, Kenneth C Anderson, Peter J Campbell, Nikhil C Munshi
Abstract
Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number profiling and cytogenetics to analyse 84 myeloma samples. Most cases have a complex subclonal structure and show clusters of subclonal variants, including subclonal driver mutations. Serial sampling reveals diverse patterns of clonal evolution, including linear evolution, differential clonal response and branching evolution. Diverse processes contribute to the mutational repertoire, including kataegis and somatic hypermutation, and their relative contribution changes over time. We find heterogeneity of mutational spectrum across samples, with few recurrent genes. We identify new candidate genes, including truncations of SP140, LTB, ROBO1 and clustered missense mutations in EGR1. The myeloma genome is heterogeneous across the cohort, and exhibits diversity in clonal admixture and in dynamics of evolution, which may impact prognostic stratification, therapeutic approaches and assessment of disease response to treatment.
Figures
References
- Fonseca R. et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 23, 2210–2221 (2009).
- Bergsagel P. L. & Kuehl W. M. Molecular pathogenesis and a consequent classification of multiple myeloma. J. Clin. Oncol. 23, 6333–6338 (2005).
- Hideshima T., Mitsiades C., Tonon G., Richardson P. G. & Anderson K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer. 7, 585–598 (2007).
- Morgan G. J., Walker B. A. & Davies F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer. 12, 335–348 (2012).
- Chapman M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467–472 (2011).
- Egan J. B. et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 120, 1060–1066 (2012).
- Walker B. A. et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood 120, 1077–1086 (2012).
- Walker B. A. et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28, 335–341 (2013).
- Keats J. J. et al. Clonal competition with alternating dominance in multiple myeloma. Blood 120, 1067–1076 (2012).
- Magrangeas F. et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27, 473–481 (2012).
- Nik-Zainal S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).
- Aparicio S. & Caldas C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 368, 842–851 (2013).
- Landau D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714–726 (2013).
- Alexandrov L. B., Nik-Zainal S., Wedge D. C., Campbell P. J. & Stratton M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013).
- Alexandrov L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
- Lawrence M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
- Roberts S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).
- Anderson K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361 (2011).
- Campbell P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109–1113 (2010).
- Gerlinger M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
- Greaves M. & Maley C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012).
- Nik-Zainal S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
- Papaemmanuil E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 365, 1384–1395 (2011).
- Welch J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
- Hwang D. G. & Green P. Bayesian Markov chain Monte Carlo sequence analysis reveals varying neutral substitution patterns in mammalian evolution. Proc. Natl Acad. Sci. USA 101, 13994–14001 (2004).
- Stephens P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404 (2012).
- Smith H. C., Bennett R. P., Kizilyer A., McDougall W. M. & Prohaska K. M. Functions and regulation of the APOBEC family of proteins. Semin. Cell Dev. Biol. 23, 258–268 (2012).
- Bergsagel P. L. & Kuehl W. M. Chromosome translocations in multiple myeloma. Oncogene 20, 5611–5622 (2001).
- Muramatsu M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553–563 (2000).
- Pasqualucci L. et al. Expression of the AID protein in normal and neoplastic B cells. Blood 104, 3318–3325 (2004).
- Kridel R. et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119, 1963–1971 (2012).
- Lohr J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109, 3879–3884 (2012).
- Maekawa M., Nakamura S. & Hattori S. Purification of a novel ras GTPase-activating protein from rat brain. J. Biol. Chem. 268, 22948–22952 (1993).
- Garnett M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).
- Prahallad A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012).
- Boyd K. D. et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin. Cancer Res. 17, 7776–7784 (2011).
- Vogelstein B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
- Madani N. et al. Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J. Virol. 76, 11133–11138 (2002).
- Browning J. L. et al. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72, 847–856 (1993).
- Demchenko Y. N. et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115, 3541–3552 (2010).
- Keats J. J. et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer cell 12, 131–144 (2007).
- Biankin A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).
- Katoh M. Function and cancer genomics of FAT family genes (review). Int. J. Oncol. 41, 1913–1918 (2012).
- Hegeman A. D., Gross J. W. & Frey P. A. Concerted and stepwise dehydration mechanisms observed in wild-type and mutated Escherichia coli dTDP-glucose 4,6-dehydratase. Biochemistry 41, 2797–2804 (2002).
- Worby C. A. & Dixon J. E. Sorting out the cellular functions of sorting nexins. Nat. Rev. Mol. Cell Biol. 3, 919–931 (2002).
- Kim J. D., Yu S., Choo J. H. & Kim J. Two evolutionarily conserved sequence elements for Peg3/Usp29 transcription. BMC Mol. Biol. 9, 108 (2008).
- Relaix F., Wei X. J., Wu X. & Sassoon D. A. Peg3/Pw1 is an imprinted gene involved in the TNF-NFkappaB signal transduction pathway. Nat. Genet. 18, 287–291 (1998).
- Liu J. et al. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J. 30, 846–858 (2011).
- Robert C., Arnault J. P. & Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr. Opin. Oncol. 23, 177–182 (2011).
- Callahan M. K. et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367, 2316–2321 (2012).
- Di Bernardo M. C. et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204–1210 (2008).
- Chen L. et al. Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma. Blood 115, 61–70 (2010).
- Palumbo A. & Anderson K. Multiple myeloma. N. Engl. J. Med. 364, 1046–1060 (2011).
- Varela I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).
- Li H. & Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589–595 (2010).
- Ye K., Schulz M. H., Long Q., Apweiler R. & Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).
- Stephens P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27–40 (2011).
- Van Loo P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910–16915 (2010).
- Tarpey P. S. et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat. Genet. 45, 923–926 (2013).
- Greenman C., Wooster R., Futreal P. A., Stratton M. R. & Easton D. F. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 173, 2187–2198 (2006).
Source: PubMed